For information about any of these trials, you may contact the individuals who are listed with each trial or study below, or you may contact us at our general USC MS Comprehensive Care Center number (323-442-6870) or email address (mscare@usc.edu).
Please note that appointments to see our doctors for non-research related care may be made by calling the Weiner Neurology Clinic at 323-442-5710.
MS-F204: A Study to Evaluate the Safety and Efficacy of Oral Fampridine-SR in Patients with MS
Status:
CLOSED. Study in follow-up
Sponsors:
Acorda
Type of Study and Brief Description:
A double-blind, placebo controlled, 13-week, parallel group study to evaluate the safety and efficacy of oral Fampridine-SR (10 mg twice a day) in patients with a definite diagnosis of any form of multiple sclerosis.
Background:
Thirteen clinical studies of Fampridine-SR have been conducted in patients with MS. This study is the second of two Phase 3 studies designed to investigate the safety and efficacy of 10 mg b.i.d. Fampridine-SR in the treatment of people with multiple sclerosis to improve disease related physical disability as measured by walking, leg
strength, and related activities of daily living.
USC Principal Investigator:
Norm Kachuck, M.D.
Contact:
Pat Guttierrez (323-442-6817 or mstcell@usc.edu)
Additional Information:
You can click here for a document that describes more about this trial.
Back to top
|
